Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19

Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, Sun C, Sylvia S, Rozelle S, Raat H, Zhou H (2020) Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 9:29. https://doi.org/10.1186/s40249-020-00646-x Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608–1621. https://doi.org/10.1093/jac/dkv018 Bishop NE (1998) Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 41:261–271. https://doi.org/10.1159/000024948 Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919–931. https://doi.org/10.1007/s40264-018-0689-4 Chen CY, Wang FL, Lin CC (2006) Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 44:173–175. https://doi.org/10.1080/15563650500514558 Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D (2020a) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 49:215–219 Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z (2020b) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.03.22.2004075 Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279–283. https://doi.org/10.1016/j.jcrc.2020.03.005 Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31:257–274. https://doi.org/10.2165/00003088-199631040-00003 EMA(European Medicines Agency) (2020) COVID-19: chloroquine and hydroxychloroquine only be used in clinical trials or emergency use programmes. Available at European Medicines Agency document Website https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf. Accessed 1 Apr 2020 FDA(US Food & Drug Administration) (2020) Re: Request for Emergency Use Authorization For Use of Chloroquine Phoslhate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Covrnavirus Disease. US Food & Drug Administration official Website. Available at https://www.fda.gov/media/136534/download. Accessed 29 Mar 2020 Frisk-Holmberg M, Bergqvist Y, Englund U (1983) Chloroquine intoxication. Br J Clin Pharmacol 15:502–503. https://doi.org/10.1111/j.1365-2125.1983.tb01540.x Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5:S11–S15 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D (2020a) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105949 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D (2020b) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Travel Med Infect Dis 34:101663. https://doi.org/10.1016/j.tmaid.2020.101663 Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 7:10–11. https://doi.org/10.1186/s40779-020-00240-0 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, Ferguson NM (2020) Report 3: transmissibility of 2019-nCoV. Feminine-Perspective Magazine Web. Available at https://fpmag.net/wp-content/uploads/2020/01/Imperial-2019-nCoV-transmissibility.pdf. Accessed 29 Mar 2020 Inglot AD (1969) Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 4:203–214. https://doi.org/10.1099/0022-1317-4-2-203 Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264–268. https://doi.org/10.1016/j.bbrc.2004.08.085 Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53:3416–3421. https://doi.org/10.1128/AAC.01509-08 Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR (2003) Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. J Inorg Biochem 94:36–42. https://doi.org/10.1016/s0162-0134(02)00633-5 Li C, Zhu X, Ji X, Quanquin N, Deng YQ, Tian M, Aliyari R, Zuo X, Yuan L, Afridi SK, Li XF, Jung JU, Nielsen-Saines K, Qin FX, Qin CF, Xu Z, Cheng G (2017) Chloroquine, a FDA-approved drug, prevents Zika Virus infection and its associated congenital microcephaly in mice. EBioMedicine 24:189–194. https://doi.org/10.1016/j.ebiom.2017.09.034 Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https://doi.org/10.1038/s41421-020-0156-0 Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology (2016) Recommendations on screening for chloroquine and hydroxychloroquine etinopathy (2016 Revision). Ophthalmology 123:1386–1394. https://doi.org/10.1016/j.ophtha.2016.01.058 Mediterranee-infection Hospital (2020) Countries and regions where hydroxychloroquine and chloroquine are recommended to fight coronavirus. Available at Mediterranee-infection Hospital Website https://www.mediterranee-infection.com/coronavirus-pays-ou-lhydroxychloroquine-est-recommandee. Accessed 28 Mar 2020 Mitjà O, Clotet B (2020) Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health 8:e639–e640. https://doi.org/10.1016/S2214-109X(20)30114-5 Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N (2020) No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50:384. https://doi.org/10.1016/j.medmal.2020.03.006 Motarjemizadeh Q, Aidenloo NS, Abbaszadeh M (2015) Detection of hydroxychloroquine retinal toxicity by automated perimetry in 60 rheumatoid arthritis patients with normal fundoscopic findings. Glob J Health Sci 8:59–64. https://doi.org/10.5539/gjhs.v8n3p59 Naarding MA, Baan E, Pollakis G, Paxton WA (2007) Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology 4:6. https://doi.org/10.1186/1742-4690-4-6 Piller C (2020) Former FDA leaders decry emergency authorization of malaria drugs for coronavirus. Science Magazine NewWeb. Available at https://www.sciencemag.org/news/2020/04/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus. Accessed 7 Apr 2020 Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653–671. https://doi.org/10.1007/s40261-018-0656-y Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450–458. https://doi.org/10.1016/0042-6822(90)90099-d Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166. https://doi.org/10.1038/s41584-020-0372-x Sermo.Com (2020) Breaking Results: Sermo’s COVID-19 Real Time Barometer Study. Available at Sermo’s COVID-19-Barometer Web https://public-cdn.sermo.com/covid19/c8/be4e/4edbd4/dbd4ba4ac5a3b3d9a479f99cc5/wave-i-sermo-covid-19-global-analysis-final.pdf. Accessed 27 Mar 2020. Shen M, Peng Z, Xiao Y, Zhang L (2020) Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. Biorxiv. https://doi.org/10.1101/2020.01.23.916726 Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S, Maeno K (1983) Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 64:1149–1156. https://doi.org/10.1099/0022-1317-64-5-1149 Srinivasa A, Tosounidou S, Gordon C (2017) Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue? J Rheumatol 44:398. https://doi.org/10.3899/jrheum.161063 Tan YW, Yam WK, Sun J, Chu JJH (2018) An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res 149:143–149. https://doi.org/10.1016/j.antiviral.2017.11.017 Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH (2002) An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Trop 83:49–61. https://doi.org/10.1016/s0001-706x(02)00056-6 Tönnesmann E, Kandolf R, Lewalter T (2013) Chloroquine cardiomyopathy—a review of the literature. Immunopharmacol Immunotoxicol 35:434–442. https://doi.org/10.3109/08923973.2013.780078 Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762. https://doi.org/10.1016/j.antiviral.2020.104762 Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69 Voss A (2020) Official Statement from International Society of Antimicrobial Chemotherapy (ISAC). Available at International Society of Antimicrobial Chemotherapy PublicationWeb https://www.isac.world/news-and-publications/official-isac-statement. Accessed 3 Apr 2020. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020a) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069. https://doi.org/10.1001/jama.2020.1585 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. https://doi.org/10.1038/s41422-020-0282-0 WHO(World Helth Organization) (2020) Coronavirus disease (COVID-19) Situation Dashboard. Available at World Helth Organization Offical Web https://www.who.int/redirect-pages/page/novel-coronavirus-(covid-19)-situation-dashboard. Accessed 30 Apr 2020 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:1–11. https://doi.org/10.1001/jamainternmed.2020.0994 Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23:300–302. https://doi.org/10.1038/cr.2012.165 Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY (2014) Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 30:1706–1715. https://doi.org/10.1016/j.cjca.2014.08.016 Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730–1741. https://doi.org/10.1111/all.14238 Zou L, Xue Y, Jones M, Heinbockel T, Ying M, Zhan X (2018) The effects of quinine on neurophysiological properties of dopaminergic neurons. Neurotox Res 34:62–73. https://doi.org/10.1007/s12640-017-9855-1